Evidence map›Paper›PMID 40901193›Full record

ReviewAnnals of medicine and surgery (2012)2025

Advances and controversies in acute decompensated heart failure treatment: beta-blocker roles, emerging devices, and future directions.

Fathi Milhem, Omar Almur, Orabi Hajjeh, Mohammad Bdair, Abdelfattah M Dahmas, Karol B Haddad, Abdalhakim Shubietah, Osama S Al-Said, Rama Al-Braik, Maram M Abukhalil and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Fathi MilhemFaculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Omar AlmurFaculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Orabi HajjehFaculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Mohammad BdairFaculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Abdelfattah M DahmasFaculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.ORCID https://orcid.org/0009-0000-6734-8341
Karol B HaddadFaculty of Medicine, Arab American University, Jenin, Palestine.
Abdalhakim ShubietahInternal Medicine Department, Advocate Illinois Masonic Medical Center, Chicago, Illinois.
Osama S Al-SaidFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Rama Al-BraikFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Maram M AbukhalilFaculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Qutayba Z AyasehFaculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Hammam JalladFaculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Lina KarakiFaculty of Medicine, Al-Quds University, Jerusalem- Abu Dies, Palestine.
Husam HamshariFaculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Mohammed AbuBahaFaculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acutely decompensated heart failure (AHF) is a severe, multifactorial syndrome with acute symptom worsening, which poses a great challenge for healthcare professionals worldwide. AHF admissions are responsible for a high percentage of morbidity, mortality, and healthcare utilization, particularly in elderly comorbid patients. The pathophysiology, clinical presentation, and treatment of AHF are presented in this review, emphasizing neurohormonal activation, hemodynamic derangements, and comorbidities such as chronic kidney disease, chronic obstructive pulmonary disease, and atrial fibrillation. Diagnostic and therapeutic approaches, including the use of beta-blockers, inotropes, and developing device-based therapies, are addressed. Controversies central to the discussion are the balancing of relief of symptoms with the possibility of adverse effects of high-dose inotropes and diuretics, the contentious continuation of beta-blockade in acute decompensation, and the emerging fluid management techniques, including ultrafiltration and the use of SGLT2 inhibitors. Also featured are promising advances in the areas of biomarker-directed therapies, regenerative medicine, and RNA-based therapies. New devices and telemedicine platforms are some of the emerging technologies underlining the shift toward precision medicine and multidisciplinary care. Despite progress being made, AHF is a heterogeneous and developing field, and further research and innovation are necessary. The intersection of pharmacological innovation, personalized medicine, and digital health offers new possibilities for the enhancement of outcomes, demanding collaboration among clinicians, researchers, and policymakers in addressing the ongoing challenges of this high-burden state.

Indexed as

acute decompensated heart failure (ADHF)biomarker-guided treatmentemerging therapiesmanagement strategiespathophysiology

Identifiers

PMID40901193
PMCPMC12401334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.